Intellia Therapeutics NTLA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$394.6M+25.0% | -$412.69M+20.5% | -$445.81M+14.6% | -$480.19M+5.6% | -$525.91M-8.3% | ||
| $9.48M-7.6% | $9.78M-4.9% | $9.96M-2.1% | $10.16M+3.0% | $10.26M+8.8% | ||
| $71.86M-49.4% | $80.22M-48.0% | $103.1M-31.1% | $123.11M-15.3% | $141.94M+0.7% | ||
| —— | —— | —— | -$975K-113% | -$25.92M-182% | ||
| $6.44M— | $5.99M— | $464K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $39.54M+379% | $26.35M+608% | $17.12M+59.7% | -$16.8M-161% | -$14.15M-145% | ||
| -$29.68M-36.1% | -$28.11M-27.3% | -$19.98M— | -$20.54M— | -$21.8M— | ||
| $1.22M+104% | $0+100% | -$429K+98.5% | -$6.93M+73.8% | -$28.63M-372% | ||
| -$363.15M+3.7% | -$394.74M-13.1% | -$410.65M-15.1% | -$418.58M-12.1% | -$377.15M+7.0% | ||
| $473K-88.2% | $1.13M-80.5% | $1.98M-68.6% | $3.23M-65.5% | $4.01M-68.3% | ||
| $200.75M-6.2% | $228.77M+82.2% | $352.8M— | $345.09M— | $213.99M— | ||
| —— | $128.18M-27.5% | $172.16M+44.6% | $173.76M+42.8% | $174.94M+44.6% | ||
| $165.06M+31.3% | $131.49M-29.2% | $131.83M-54.5% | $99.16M-56.3% | $125.76M-33.1% | ||
| —— | —— | —— | —— | —— | ||
| $4.11M-72.2% | $5.86M-67.1% | $8.63M-57.9% | $11.83M-51.0% | $14.81M-44.3% | ||
| $1.22M+104% | $0+100% | -$429K+98.5% | -$6.93M+73.8% | -$28.63M-372% | ||
| -$38.76M+8.8% | -$54.95M-206% | -$54.56M-200% | -$54.61M-212% | -$42.51M-154% | ||
| -$34.28M-44.4% | -$33.09M-54.1% | -$31.21M-56.8% | -$27.65M-41.1% | -$23.73M-22.9% | ||
| -$16.56M— | -$2.81M— | —— | —— | —— | ||
| $39.54M+379% | $26.35M+608% | $17.12M+59.7% | -$16.8M-161% | -$14.15M-145% | ||
| -$50K— | $32K— | $203K— | —— | —— | ||
| -$29.68M-36.1% | -$28.11M-27.3% | -$19.98M— | -$20.54M— | -$21.8M— | ||
| —— | $0-100% | $28.21M-66.8% | $56.41M-1.1% | $84.62M+190% | ||
| —— | —— | —— | —— | —— | ||
| -$363.63M+4.6% | -$395.87M-11.6% | -$412.63M-13.7% | -$421.82M-10.2% | -$381.16M+8.8% | ||
| -$363.63M+4.6% | -$395.87M-11.6% | -$412.63M-13.7% | -$421.82M-10.2% | -$381.16M+8.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Intellia Therapeutics's cash flow data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.